Adagene Inc. announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co. Inc., Rahway, NJ, USA's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with metastatic Microsatellite-stable (MSS) colorectal cancer (CRC). This enables the company to broaden its dose expansion cohorts for MSS CRC at selected dosing regimens, and potentially in other tumor types.

Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024: Follow up of Part 1 evaluable patients at 10 mg/kg Q3W (n=12) and 10 mg/kg Q6W (n=10); Data from Part 2 patients at 10 mg/kg quarter3W (n=12); Evaluation of 20 mg/kg loading doses for Project Optimus requirements: Safety data with repeat doses; Dose expansion in MSS CRC (n~10); Additional patients in China (n 10).